Search Results

Search results for "Antibodies", has returned "10" results.

Invalidity of a Patent Claiming Antibodies Characterized by Their Function In View of Amgen

Invalidity of a Patent Claiming Antibodies Characterized by Their Function In View of Amgen January 12, 2024 Baxalta Inc. and Baxalta GmbH (Baxalta) appealed a district court decision that the claims ...

Is There Any Hope For Antibody Patents in the United States?

Is There Any Hope For Antibody Patents in the United States? January 25, 2022 Conclusion Okay, let’s get this out of the way up front. The answer is maybe… but only with a lot more work and with ...

Jenna Logsdon, Ph.D. - Blogs

Invalidity of a Patent Claiming Antibodies Characterized by Their Function In View of Amgen Attorney: Marina I. Miller, Ph.D. January 12, 2024 Baxalta Inc. and Baxalta GmbH (Baxalta) appealed a district ...

Must a "Human Antibody" Be Entirely Human? Or May It Also Be "Partially Human?"

Must a "Human Antibody" Be Entirely Human? Or May It Also Be "Partially Human?" October 16, 2020 This is a consolidated appeal from two Patent Trial and Appeal Board (“Board”) decisions in inter ...

Jenna Logsdon, Ph.D. - Blogs

Follow-On IPR Petitions - Institution Is Not Impossible But Difficult

1. An isolated human antibody that competes with a reference antibody for binding to human IL-4 interleukin-4 (IL-4) receptor, wherein the light chain of said reference antibody comprises the amino acid ...

The Federal Circuit's First Enablement Decision Since Amgen

antibodies against Factor VIII). The ‘590 patent sought to treat hemophilia with antibodies which increase the procoagulant activity of Factor IXa by binding to Factor IX/IXa. The court identified Claim ...

Amgen v. Sanofi – Impermissible Functional Claiming?

district court’s decision on JMOL that Amgen’s antibody claims lacked an enabling disclosure. Much of the argument revolved around what was the quantum of experimentation that was too much for a claim ...

Homepage

Two Herceptin® Patents Survive IPR: A Lesson in Separately Arguing Motivation to Combine and Reasonable Expectation of Success

Herceptin®, the brand name for the monoclonal antibody drug trastuzumab, has been federally approved since 1998 primarily for treating breast cancer. Herceptin® has been extremely successful for Genentech,...